ArticleInternal medicine (Tokyo, Japan)2021

Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.

Masahiko Chiwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.